9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends NMTR vs. THAR, KTTA, ATXI, SNOA, CPHI, GENE, ARTL, APM, TCRT, and SNPXShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Tharimmune (THAR), Pasithea Therapeutics (KTTA), Avenue Therapeutics (ATXI), Sonoma Pharmaceuticals (SNOA), China Pharma (CPHI), Genetic Technologies (GENE), Artelo Biosciences (ARTL), Aptorum Group (APM), Alaunos Therapeutics (TCRT), and Synaptogenix (SNPX). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Tharimmune Pasithea Therapeutics Avenue Therapeutics Sonoma Pharmaceuticals China Pharma Genetic Technologies Artelo Biosciences Aptorum Group Alaunos Therapeutics Synaptogenix Tharimmune (NASDAQ:THAR) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends. Which has better valuation and earnings, THAR or NMTR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$9.32MN/AN/A9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Which has more risk and volatility, THAR or NMTR? Tharimmune has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Does the MarketBeat Community favor THAR or NMTR? 9 Meters Biopharma received 37 more outperform votes than Tharimmune when rated by MarketBeat users. CompanyUnderperformOutperformTharimmuneN/AN/A9 Meters BiopharmaOutperform Votes3771.15% Underperform Votes1528.85% Do insiders and institutionals believe in THAR or NMTR? 1.2% of Tharimmune shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 2.4% of Tharimmune shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to THAR or NMTR? In the previous week, Tharimmune had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Tharimmune and 0 mentions for 9 Meters Biopharma. Tharimmune's average media sentiment score of 0.50 beat 9 Meters Biopharma's score of 0.00 indicating that Tharimmune is being referred to more favorably in the media. Company Overall Sentiment Tharimmune Positive 9 Meters Biopharma Neutral Is THAR or NMTR more profitable? Tharimmune's return on equity of -167.63% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -167.63% -130.18% 9 Meters Biopharma N/A -584.97%-159.45% SummaryTharimmune beats 9 Meters Biopharma on 6 of the 9 factors compared between the two stocks. Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$164.93M$5.07B$8.89BDividend YieldN/A3.25%4.99%4.07%P/E Ratio-0.02329.4783.5712.93Price / SalesN/A14,939.521,220.3088.33Price / CashN/A11.6739.4636.25Price / BookN/A7.116.936.25Net Income-$43.77M-$18.52M$119.12M$225.93M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220THARTharimmune0.3961 of 5 stars$2.71+8.4%N/A-96.1%$4.04MN/A0.002Gap DownKTTAPasithea Therapeutics1.3273 of 5 stars$3.16-0.9%N/A-50.4%$4.01M$20,000.000.003News CoverageGap DownATXIAvenue Therapeutics1.4277 of 5 stars$2.06+2.5%N/A-86.7%$3.94MN/A0.114Negative NewsGap DownSNOASonoma Pharmaceuticals0.839 of 5 stars$2.92+2.8%N/A+1,381.5%$3.91M$12.73M0.00180CPHIChina PharmaN/A$0.19+1.6%N/A-59.6%$3.75M$7.01M0.00231GENEGenetic Technologies0.2144 of 5 stars$0.77flatN/AN/A$3.71M$5.03M0.0050High Trading VolumeARTLArtelo Biosciences3.2257 of 5 stars$1.14-0.9%$5.00+338.6%-8.7%$3.68MN/A0.005Analyst RevisionAPMAptorum Group0.3434 of 5 stars$0.71-3.5%N/A-54.6%$3.68M$430,000.000.0030Gap DownTCRTAlaunos TherapeuticsN/A$2.27+6.6%N/A-81.3%$3.63MN/A0.0040SNPXSynaptogenix2.0975 of 5 stars$2.60-1.9%$14.00+438.5%-59.2%$3.54MN/A0.004Negative News Related Companies and Tools Related Companies THAR Alternatives KTTA Alternatives ATXI Alternatives SNOA Alternatives CPHI Alternatives GENE Alternatives ARTL Alternatives APM Alternatives TCRT Alternatives SNPX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NMTR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMTR Stock Alerts